Randomised Controlled TrialiVNSn = 242

Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial

Tesser JRP, Crowley AR, Box EJ, June JP, Wickersham PB, Valenzuela GJ, Gaylis NB, Lam GKW, Pacheco LA, Ridley DJ, et al.

Nature Medicine · 2026

Key finding

ACR20 rates were higher with active simulation than with sham at 3 months (35.2% versus 24.2%, P = 0.0209), which further improved in open-label to 50.0% at 6 months and 52.8% at 12 months (all-completers).

Condition
Rheumatoid Arthritis
Stimulation
iVNS
Evidence tier
Randomised Controlled Trial
Participants
242
View on DOI

Cite this study

Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., Gaylis, N. B., Lam, G. K. W., Pacheco, L. A., Ridley, D. J., Pinto-Patarroyo, G. P., Novack, S. N., Churchill, M. A., Kohler, M., Lee, E. C., Pando, J. A., Parris, G. R., Peterson, J. R., Shah, T., … Chernoff, D. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine, 32(1), 369-378. https://doi.org/10.1038/s41591-025-04114-7

Related studies in Rheumatoid Arthritis

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.